BioPharma APAC - Leading Source of Biopharmaceutical Intelligence in Asia Pacific

Bio Analysis

The 10 Deals That Defined APAC Biopharma in 2026

The biggest pharma deals of 2026 with an Asia-Pacific principal are easy to list and hard to rank. The ten on this page carry more than US$70 billion in he...

September 25, 2026 | Analysis

Every First Approval in APAC, 2026: The Full List

Asia-Pacific’s New Drug Boom: 99 Approvals, 20 World Firsts Somewhere in the second week of January, a BeOne Medicines BCL2 inhibitor called sonroto...

September 23, 2026 | Analysis

Why 10,000 Koreans a Year Still Fly Abroad for Stem Cell Treatment

METHOD IN BRIEF This feature expands entry 21 of our year-end count, 2026 in 26 Numbers. Every figure is cited to a regulator publication, offi...

September 21, 2026 | Analysis

2026 in 26 Numbers: The APAC Biopharma Year, Counted

METHOD IN BRIEF A number qualifies for this list only if it is sourced to a company disclosure, regulator publication, exchange filing or peer-...

September 21, 2026 | Analysis

The Arbitrage Triangle

METHOD IN BRIEF Flow estimates come from published government statistics and press reporting of official material; no authority in the region publishes in...

September 09, 2026 | Analysis

Where the Longevity Money Actually Goes

METHOD IN BRIEF Window: 1 January to 31 August 2026 for round-level claims, with full-year 2024 and 2025 figures for context. Attribution follows scientif...

September 07, 2026 | Analysis

Nobody Is the Payer

A gerotherapeutic that delays five diseases by three years each would produce savings across five budget lines over thirty years, and a cost that lands in ...

September 04, 2026 | Analysis

Food, Drug, or Neither

Yesterday was the deadline. Japan's Consumer Affairs Agency has stated that the revised labelling provisions and mandatory Good Manufacturing Practice sta...

September 03, 2026 | Analysis

The Accidental Gerotherapeutic

METHOD IN BRIEF Outcome evidence in this article is taken from published trial results and approved label language only. No efficacy or outcome claim is s...

August 31, 2026 | Analysis

The Biological Age Business

On coming 4th September at six in the evening Singapore time, a public consultation will close. It opened on 7 August, it is still open as this is publishe...

August 27, 2026 | Analysis

The Sarcopenia Definition Race: The Endpoint Is the Asset

In a category with no approvable indication anywhere in the world, whoever writes the endpoint definition controls who is eligible for a trial, what counts...

August 12, 2026 | Analysis

Reading the Register: What Japan's Provision Plans Actually Say

A register, not an approval list Start with the thing that is most often got wrong, including by people who should know better. The Act on the Safety of ...

August 10, 2026 | Analysis

9 AI Drug Discovery Platforms Built in Asia-Pacific, and What They Have Actually Shipped

For most of the past decade, the only honest answer to the question of whether AI drug discovery works in Asia-Pacific was that nobody could yet know. The ...

August 04, 2026 | Analysis

12 Funding Rounds That Show Where APAC Biotech Capital Is Going

There is a version of this story that lists twelve press releases and calls it analysis. This is not that story. Every round below has already been announc...

July 30, 2026 | News

Stay Connected